



Minutes

Date Wednesday, 07/06/2023

Time 9:00 AM

To Committee Members

At Virtual via Microsoft Teams

Subject AWERB 3Rs Committee

AWERB 3Rs Committee: [REDACTED]

In Attendance: [REDACTED]

Apologies:

Minutes – [REDACTED]

1. Minutes

Minutes from the meeting held on 3rd May 2023 were approved.

2. Matters Arising

None

3. Retrospective Reviews

The committee discussed the following:

[REDACTED] - Provision of an outsourced drug discovery platform for the development of therapeutic drugs for cancer. *This licence is being transferred to another PLh*

- There were no comments on for this RR

[REDACTED] - Breeding and maintenance of germ free and gnotobiotic animals service licence. *This licence is being transferred to another PLh*

- Document needs to be checked for any errors and to ensure it is relevant to the specific licence.
- All yes/no questions need to be answered depending on animal use on the individual retrospective reviews.
- Any publications or achievements need to be included these as they are not captured on the next project licence holder's retrospective review.
- Section 2.10. Statement in this section be removed.
- Section 2.11. Remove the sources of animals listed in this section.



██████████ - Development of Live Bacterial Therapeutics to treat diseases with intestinal dysbiosis. *This licence is being transferred to another PLh*

- Document needs to be checked for any errors and to ensure it is relevant to the specific licence.
- All yes/no questions need to be answered depending on animal use on the individual retrospective reviews.
- Any publications or achievements need to be included as they are not captured on the next project licence holder's retrospective review.
- Section 2.1. Total boxes to be completed in the table where mice have been used.
- Section 2.2. Table for protocols 1 and 4 where some mice experienced lower than expected severity is needed
- Section 2.3. The number of mice used to be reviewed and amended as necessary. This also applies to the percentage in section 2.4.

██████████ - Development of Live Bacterial Therapeutics for the treatment of cancer. *This licence is being transferred to another PLh*

- All RR submitted to be checked for spelling and grammar errors.
- Any yes/no questions to be answered as appropriate depending on animal use on the individual retrospective reviews.
- Any publications or achievements that have happened under the licences to be included these as they are not captured on the next project licence holder's retrospective review.
- Section 2.1. The total boxes to be completed.
- Section 2.5. This section to be completed as significantly fewer animals have been used on all protocols.

4. Amendments

5. Severe Severity

6. Severe Severity licence reviews

7. Standard condition 18 reports

20/01/23

There have been 10 SC18 since the last meeting. None have been repeats.

17/02/23

There have been 31 Standard Condition 18's since the last meeting with repeat issues regarding Weight loss; Microchip bruising/haemorrhage; i/p injection; o/g technique; miss-dose; saphenous bleed bruising. FM explained that there has been some saphenous bleed bruising alongside the issue with the chipping and she is looking into this.

17/03/23

In the last month there have been 32 Standard condition 18's submitted, and repeat concerns were microchips, gavage, mis-dose, restraint, weight loss and tumour overgrowth.

21/04/23



There have been 43 HO Standard Condition 18's in the last month. The commonalities have been weight loss. A few of those have been due to doxycycline. Other commonalities are microchip bruising and haemorrhage, nose bleeds, Tamoxifen animals, and metastatic tumour.

8. 3Rs information/reports

9. Highlights of AWERB Standing meeting*

10. Highlights of January AOC meeting*

11. Any Other Business

12. For information only

Date of next meeting: Wednesday 5th July 2023 via MS Teams. The next in person meeting will be 2nd August.

***Items for information only unless un-starred by committee member**